To learn more about this report, request sample copy
North America remains the dominant region in the global canine influenza vaccine market and is anticipated to hold 44.8% of the market share in 2024. The U.S. accounts for the bulk of the demand due to high pet adoption and awareness about canine health. Pet owners in the US are highly inclined towards vaccinating their dogs regularly due to ease of availability and recommendation by veterinarians. Major players, such as Zoetis, Merck, and Boehringer Ingelheim, have established robust distribution networks across veterinary clinics and pharmacies in the country to cater to the needs of dog owners. This widespread supply chain coupled with new product introductions at regular intervals has helped sustain the leadership position of North America in the global market.
The Asia Pacific region has emerged as the fastest growing market for canine influenza vaccines in recent years. Rising pet ownership in China and India due to changing socio-economic demographics is significantly driving the demand. With a growing middle class, more people are able to afford pet healthcare expenses. This provides avenues for vaccine companies to increase penetration in Asia Pacific through effective marketing strategies and tie-ups with local retail chains. However, lack of adequate veterinary infrastructure in rural areas acts as a barrier. But expanding veterinary clinics and hospitals in Tier I and Tier II cities are expected to boost the future sales potential. Further, regional vaccine manufacturers improving their R&D capabilities and production capacities will help Asia Pacific consolidate its status as a hotspot for high growth in the canine influenza vaccine market over the coming decade.
Global Canine Influenza Vaccine Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients